Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

DeFi Development Corp. to Host X Spaces to Discuss Latest $125 Million Equity Raise

BOCA RATON, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) today announced it will host a live X Spaces event on Wednesday, August 27, 2025, at 4:30 P...

How does this funding round compare to recent capital raises by peer DeFi‑focused public companies in terms of size, valuation, and market reaction? What specific use‑of‑proceeds or strategic initiatives were outlined that could drive revenue or margin expansion? How will the $125 million equity raise impact dilution and the company's earnings per share?
Symbol: DFDV
Funding
about 12 hours ago
Read more globenewswire

Okta Announces Second Quarter Fiscal Year 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Okta, Inc. (Nasdaq: OKTA), the leading independent identity partner, today announced financial results for its second quarter ended July 31, 2025. “Okta’s unified id...

How are the new product adoption and public sector growth impacting Okta's revenue mix and competitive positioning versus peers? What guidance did Okta provide for Q3 and FY2026, and how does it compare to analyst expectations? Did Okta beat or miss consensus revenue and EPS estimates for Q2 FY2026?
Symbol: OKTA
Earnings
about 12 hours ago
Read more businesswire

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerati...

How might the regained compliance affect the stock's eligibility for inclusion in index funds and its overall liquidity? Is there a risk that the company's bid price could fall below the $1 threshold again, prompting another delisting warning? Will the reinstatement of Nasdaq compliance trigger a short‑cover rally or increased buying pressure on CGTX?
Symbol: CGTX
Regulation
about 12 hours ago
Read more globenewswire

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Company to host conference call at 8 a.m. ET, August 27, 2025 Company to host conference call at 8 a.m. ET, August 27, 2025

What potential does this trial success have to expand BioXcel's pipeline and partnership opportunities? How does the efficacy and safety data from SERENITY compare to existing treatments for agitation in bipolar disorder and schizophrenia? What are the expected market implications of the SERENITY trial topline results on BioXcel's valuation?
Symbol: BXCX
Clinical trials
about 12 hours ago
Read more globenewswire